Intravenous Lipopolysaccharide Challenge in Healthy Participants Reveals Pharmacodynamic Markers in Blood and Bone Marrow for Early‐Phase Oncology Drug Development
Authors:
- Igor RadanovićIRIgor Radanović
- Ingrid TomljanovićITIngrid Tomljanović
- Wieke H. GrievinkWGWieke H. Grievink
- Diana R. PereiraDPDiana R. Pereira
- Peter van BalenPBPeter van Balen
- Maria J. JuachonMJMaria J. Juachon
- Marieke L. de KamMKMarieke L. de Kam
- Lisa PaganLPLisa Pagan
- Manon A.A. JansenMJManon A.A. Jansen
- Matthijs MoerlandMMMatthijs Moerland
- Jacobus J. BoschJBJacobus J. Bosch
Open Access
- 14 April 2026
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 120 (5) , 1301-1314
Abstract
Demonstrating pharmacological effects in early‐phase oncology clinical trials remains challenging, largely due to the lack of robust pharmacodynamic markers. Lipopolysaccharide (LPS) is used as an immune challenge agent in healthy participants to study drugs for autoimmune conditions. We hypothesized that the intravenous LPS challenge model could be implemented in oncology drug studies in healthy participants to evaluate in vivo pharmacodynamics of new drugs. This open‐label study included 13 healthy males who received a single intravenous dose of 1 or 2 ng/kg LPS. Blood and bone marrow samples were collected pre‐ and post‐LPS for bulk RNA sequencing, multiplex cytokine measurements, immunophenotyping, and immunohistochemistry of bone marrow biopsies. Differentially expressed genes were integrated with the OpenTargets Platform and the COSMIC database to assess their tractability and relation to cancer hallmarks. The LPS challenge and bone marrow sampling were safe and well tolerated. In peripheral blood, LPS induced a rapid, transient inflammatory response, with myeloid cell activation and enrichment of inflammation‐related pathways. Conversely, bone marrow showed an attenuated cellular response and activation of hematopoietic and cell cycle‐related transcriptional programs. We identified 91 LPS‐induced oncology‐relevant targets in blood and 24 targets in bone marrow. The oncogenic transcription factor MYC was upregulated in the bone marrow, which was confirmed at the protein level by a dose‐dependent increase in c‐Myc expression. Our findings highlight the potential of immune challenges in healthy participants to pharmacodynamically profile novel oncology agents, with the aim of generating early pharmacological data ahead of pivotal clinical trials in cancer patients.Keywords
This publication has 49 references indexed in Scilit:
- Hallmarks of cancer—Then and now, and beyondCell, 2026
- Intra-tumoral immunomodulatory therapy for advanced abdominal cancers using lipopolysaccharide: The Regional Immuno-Oncology Trial-1 (RIOT-1) protocol (NCT05751837)Surgical Oncology Insight, 2024
- Impact of pharmacodynamic biomarkers in immuno-oncology phase 1 clinical trialsEuropean Journal of Cancer, 2022
- Clinical, Cellular, and Molecular Effects of Corticosteroids on the Response to Intradermal Lipopolysaccharide Administration in Healthy VolunteersClinical Pharmacology & Therapeutics, 2022
- MYC as a target for cancer treatmentCancer Treatment Reviews, 2021
- Challenging the challenge: A randomized controlled trial evaluating the inflammatory response and pain perception of healthy volunteers after single-dose LPS administration, as a potential model for inflammatory pain in early-phase drug developmentBrain, Behavior, and Immunity, 2020
- Differentiation and activation of eosinophils in the human bone marrow during experimental human endotoxemiaJournal of Leukocyte Biology, 2020
- RNA-seq analysis of LPS-induced transcriptional changes and its possible implications for the adrenal gland dysregulation during sepsisThe Journal of Steroid Biochemistry and Molecular Biology, 2019
- Safety, Pharmacokinetics, and Pharmacodynamics of ME-401, an Oral, Potent, and Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Following Single Ascending Dose Administration to Healthy VolunteersClinical Therapeutics, 2018
- Hallmarks of Cancer: The Next GenerationCell, 2011